MARKET

GENB

GENB

Generate Biomedicines
NASDAQ
16.12
+0.13
+0.81%
After Hours: 16.06 -0.06 -0.37% 19:30 08/21 EDT
OPEN
16.10
PREV CLOSE
15.99
HIGH
16.70
LOW
15.91
VOLUME
831.85K
TURNOVER
--
52 WEEK HIGH
18.18
52 WEEK LOW
11.00
MARKET CAP
2.07B
P/E (TTM)
-10.1314
1D
5D
1M
3M
1Y
5Y
1D
Nvidia Holds More Than 122 Million Shares of SPCX Stock After Q2. Barchart Data Shows It’s Making a High-Upside Bet.
Barchart · 5d ago
Morgan Stanley Sticks to Its Buy Rating for Generate Biomedicines, Inc. (GENB)
TipRanks · 6d ago
Weekly Report: what happened at GENB last week (0810-0814)?
Weekly Report · 6d ago
Nvidia discloses big stake in SpaceX in Q2 moves
Seeking Alpha · 08/14 21:04
Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech News
Seeking Alpha · 08/10 23:22
Weekly Report: what happened at GENB last week (0803-0807)?
Weekly Report · 08/10 10:33
Piper Sandler Remains a Buy on Generate Biomedicines, Inc. (GENB)
TipRanks · 08/07 12:09
Generate Biomedicines, Inc. reports Q2 results
Seeking Alpha · 08/06 17:17
More
About GENB
Generate Biomedicines, Inc. is a clinical-stage generative biology company focusing on the Artificial intelligence (AI) revolution in biotechnology and drug design and development. The Company is engaged in the field of generative biology using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its Generate Platform integrates generative and predictive models that learn design principles from proprietary data and graph neural networks, among other architectures. Its lead product candidate, GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma. Its other product candidates include GB-4362, a systemically administered monoclonal antibody designed to neutralize free monomethyl auristatin E (MMAE) as an adjunctive therapy to antibody-drug conjugate (ADC) molecules with an MMAE payload, as well as GB-5267, an armored, MUC16-directed CAR-T cell therapy candidate.

Webull offers Generate Biomedicines Inc stock information, including NASDAQ: GENB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GENB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GENB stock methods without spending real money on the virtual paper trading platform.